# ClinicalTrials.gov record NCT04064411

> PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct04064411-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-02-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04064411-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04064411-abaloparatide-v1.json
- Content SHA-256: `82ba724412f3cc3859837fd16399bd2942d3e84a30f5da95369ba9a1b1dbbf3e`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04064411 ([`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`](#source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`](#source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`](#source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`](#source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb))

## Sources

<a id="source-ctg-observation-nct04064411-2023-02-15-2de8099e71bb"></a>
- **ClinicalTrials.gov record NCT04064411 · retained source version 2023-02-15:2de8099e71bb8b25709a1e70af99bea80dbd8034b3340592feff24ef551e26ba** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04064411) (`ctg-observation-nct04064411-2023-02-15-2de8099e71bb`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04064411." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04064411-abaloparatide-v1.json SHA-256: 82ba724412f3cc3859837fd16399bd2942d3e84a30f5da95369ba9a1b1dbbf3e.